# Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer

> **NCT07741630** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 20 (estimated)

## Conditions studied

- PROC

## Interventions

- **DRUG:** Mirvetuximab soravtansine
- **DRUG:** Suvemcitug

## Key facts

- **NCT ID:** NCT07741630
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07741630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07741630, "Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07741630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*